A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
NCT05984602
Recruiting
The goal of this Single Arm Phase Ib clinical trial is to test standard of care chemotherapy and anti PD1 and IL1b to evaluate the safety and preliminary toxicity of this quadruplet regimen prior to resection in patients with pancreatic cancer. The main objectives it aims to answer are to: * Determine the recommended Phase II dose regimen of canakinumab and tislelizumab in combination with gemcitabine and nab-paclitaxel in patients with localized pancreatic ductal adenocarcinoma. * Estimate the... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/11/2025
Locations: Ambulatory Care Center, New York, New York +2 locations
Conditions: Pancreatic Cancer
Register for Updates
An Exercise Prehabilitation Intervention for Improving Mobility and Recovery Outcomes in Patients Undergoing Head and Neck Cancer Surgery
NCT06079697
Recruiting
This clinical trial evaluates a prehabilitation exercise intervention for improving mobility and recovery outcomes in patients undergoing surgery for head and neck cancer. Prehabilitation focuses on optimizing health before surgery in order to improve outcomes after surgery. Prehabilitation may include aspects of nutrition, exercise, mental health, or a combination of these. Exercise has been proven to improve anxiety, depression, fatigue, health related quality of life, and physical function am... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
04/11/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Head and Neck Carcinoma
Register for Updates
Brain Mechanisms of Reducing Polysubstance Use
NCT06324786
Recruiting
The proposed study will test whether neurofeedback (NF) could optimize integrative body-mind training (IBMT) practice.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: YiYuan Tang, Phoenix, Arizona
Conditions: Multiple Drug Use
Register for Updates
Speech Motor Learning and Retention (Master Protocol)
NCT06467292
Recruiting
The overall goal of this research is to test a new model of speech motor learning, whose central hypothesis is that learning and retention are associated with plasticity not only in motor areas of the brain but in auditory and somatosensory regions as well.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
04/11/2025
Locations: Yale Child Study Center, New Haven, Connecticut
Conditions: Speech
Register for Updates
Safety and Effectiveness of Physician-Modified Fenestrated and Branched Aortic Endografting for the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms
NCT06501872
Recruiting
The primary clinical objective of this study is to evaluate the safety and effectiveness of a physician-modified, fenestrated and branched aortic endoprosthesis for the treatment of thoracoabdominal aortic aneurysms (TAAAs). The goal of the primary analysis is to demonstrate both the safety and effectiveness of using a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft as compared to previously published results of open surgical replacement of the aneurysmal aorta.
Gender:
ALL
Ages:
Between 50 years and 95 years
Trial Updated:
04/11/2025
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Aortic Aneurysm
Register for Updates
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
NCT06615557
Recruiting
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/11/2025
Locations: Vistagen Clinical Site, Little Rock, Arkansas +16 locations
Conditions: Social Anxiety Disorder (SAD)
Register for Updates
Cannabis Effects on Sleep, Circadian Rhythms, and Light Sensitivity in Young Adults
NCT06743373
Recruiting
The goal of this study is to learn how cannabis use and discontinuation affect sleep, circadian rhythms, and sensitivity to light. The main questions it aims to answer are: 1. Does cannabis use and discontinuation impact sleep drive? 2. Does cannabis use and discontinuation impact light sensitivity and circadian phase?
Gender:
ALL
Ages:
Between 18 years and 25 years
Trial Updated:
04/11/2025
Locations: Western Psychiatric Hospital (Thomas Detre Hall), Pittsburgh, Pennsylvania
Conditions: Cannabis Use, Sleep, Circadian Rhythm
Register for Updates
Gadopiclenol vs. Gadobutrol for Dynamic Contrast-Enhanced Pituitary MRI (Magnetic Resonance Imaging)
NCT06846853
Recruiting
This study will evaluate the efficacy and safety of Gadopiclenol, an FDA-approved contrast agent, for visualizing pituitary lesions on MR images by comparing with the comparator, Gadobutrol, a clinically widely used contrast agent. The study is double-blinded, so neither the participants nor the researchers know which contrast agent is being used during each scan to avoid the bias of results.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
04/11/2025
Locations: University of Connecticut Health Center, Farmington, Connecticut
Conditions: Contrast Enhanced Images Vs. Non-contrast Images, Gadopiclinol Enhanced Images Vs. Gadobutrol Enhanced Images
Register for Updates
Experiment 2: One Target in Many Situations
NCT06934148
Recruiting
The goal is to look for qualitative differences in visual search behavior when one search is performed many times in a row compared to when multiple search tasks are intermixed. Four search tasks are tested. The target is the same in every task but the types of distractors change from task to task. In the Mixed condition, the four tasks are randomly changed from trial to trial. In the Blocked condition, each task is run as a block of 100 trials.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Brigham & Women's Hospital, Newton, Massachusetts
Conditions: Vision, Healthy, Attention
Register for Updates
Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
NCT02828592
Recruiting
Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a response rate with just immunosuppression for those patients lacking suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1/3 of patients are cured, 1/3 are dependent on long term... Read More
Gender:
ALL
Ages:
Between 1 year and 75 years
Trial Updated:
04/11/2025
Locations: Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia +1 locations
Conditions: Severe Aplastic Anemia
Register for Updates
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
NCT03547973
Recruiting
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: The University of Arizona Cancer Center-North Campus, Tucson, Arizona +134 locations
Conditions: Metastatic Urothelial Cancer
Register for Updates
GM-CSF With Post-Transplant Cyclophosphamide
NCT04237623
Recruiting
Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the investigators suggest that GM-CSF administration post-infusion of T-replete haploidentical stem cells and post-transplant cyclophosphamide can yield similar count recovery rates to G-CSF with a potential of lowering risk of infectious complications.
Gender:
ALL
Ages:
Between 18 years and 78 years
Trial Updated:
04/11/2025
Locations: Northside Hospital, Atlanta, Georgia
Conditions: Transplant-Related Hematologic Malignancy
Register for Updates